Relmada Therapeutics Inc. (NASDAQ: RLMD) reported 12-month interim data from its Phase 2 trial of NDV-01 for high-risk non-muscle invasive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE